Cart (Loading....) | Create Account
Close category search window
 

A Stochastic Model for Pharmaceutical R&D Project Management in a Make-or-Buy Decision Setting

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$31 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

2 Author(s)
Guozhen Zhao ; Bus. Sch., Dept. of Manage. & Global Bus., Rutgers Univ., Newark, NJ, USA ; Wen Chen

Managing a pharmaceutical R&D project is a complex undertaking that involves efforts from both business managers and scientists. The increasing complexity of exploratory activities in pharmaceutical innovation makes less likely that a project can stand alone. Project managers not only resort to in-house innovation but also external sources to propel a central project. In this paper, the authors propose a make-or-buy stochastic process model as an integrated project management tool with the goal of maximizing the successful probability of a prospective drug compound. The model illustrates the two-process-line practice in pharmaceutical R&D projects and combines this practice with the make-or-buy decision that managers always face in pharmaceuticals. Using this model, the authors discuss the decision strategies at different phases of a pharmaceutical R&D project and provide optimal solutions based on the remaining time of the project. A case study demonstrates the model's effectiveness. The model offers potential benefits in terms of its ability to transform key learning into efficient and reliable managerial decision-making practices that are well aligned with drug innovation strategies.

Published in:

Engineering Management, IEEE Transactions on  (Volume:57 ,  Issue: 3 )

Date of Publication:

Aug. 2010

Need Help?


IEEE Advancing Technology for Humanity About IEEE Xplore | Contact | Help | Terms of Use | Nondiscrimination Policy | Site Map | Privacy & Opting Out of Cookies

A not-for-profit organization, IEEE is the world's largest professional association for the advancement of technology.
© Copyright 2014 IEEE - All rights reserved. Use of this web site signifies your agreement to the terms and conditions.